




RealRate

PHARMACEUTICAL 2014

Oncotelic Therapeutics Inc
Rank 131 of 234



The relative strengths and weaknesses of Oncotelic Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Oncotelic Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 101% points. The greatest weakness of Oncotelic Therapeutics Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 81% points.

The company's Economic Capital Ratio, given in the ranking table, is 242%, being 1.2% points below the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	7,165
Cost of Goods Sold	0
Intangible Assets	93
Liabilities, Current	1,251
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	3.0
Other Revenues	95
Property and Equipment	36
Research and Development	3,636
Selling, General and Administrative Expense	4,739

Output Variable	Value in 1000 USD
Assets	7,294
Liabilities	1,251
Expenses	8,375
Revenues	95
Stockholders Equity	6,043
Net Income	-8,277
Comprehensive Net Income	-8,277
BaseVar	8,509
ECR before Limited Liability	115%
Economic Capital Ratio	242%